![G. Alexander Fleming](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
G. Alexander Fleming
No más puestos en curso
Perfil
G.
Alexander Fleming is the founder of Exsulin Corp.
He previously worked as the President & CEO of Kinexum Development LLC and as a Director at Diasome Pharmaceuticals, Inc.
Antiguos cargos conocidos de G. Alexander Fleming.
Empresas | Cargo | Fin |
---|---|---|
Kinexum Development LLC | Director Ejecutivo | 27/04/2017 |
Exsulin Corp. | Fundador | - |
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Diasome Pharmaceuticals, Inc.
![]() Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Health Technology |
Kinexum Development LLC | Miscellaneous |
Exsulin Corp. |
- Bolsa de valores
- Insiders
- G. Alexander Fleming